Venetoclax ramp-up strategies for chronic lymphocytic leukaemia in the United Kingdom: a real world multicentre retrospective study.

Abstract

This retrospective, observational study evaluated patterns of inpatient versus outpatient tumour lysis syndrome (TLS) monitoring during venetoclax ramp-up in 170 patients with chronic lymphocytic leukaemia. The primary outcome was clinical/biochemical TLS. Two clinical and four biochemical TLS occurred (4.1%). Five of the six events occurred in high-risk patients, four occurred at 20 mg dose and three at the 6-h time-point. Inpatient versus outpatient TLS rates within the high-risk subgroup were 15% and 8%. Risk category was the only predictor of TLS events in multivariate analysis. Outpatient escalation did not associate with clinically meaningful TLS events, suggesting outpatient escalation has manageable associated TLS risks, including in high-risk cohorts. These observations require confirmation in larger studies.

• Authors: Rocio Figueroa-Mora, Alexandros Rampotas, Daniel Halperin, Tina Worth, Jennifer Vidler, Dario Melotti, Paul Ferguson, Nagah Elmusharaf, Gavin Preston, Michelle Furtado, Moez Dungarwalla, Satyen Gohill, Piers Patten, Ben Kennedy, Toby A Eyre, Anna Schuh, Christopher P Fox, Tahla Munir, Nicolas Martinez-Calle
• Journal: British journal of haematology (Br J Haematol) Vol. 202 Issue 1 Pg. 48-53 (07 2023) ISSN: 1365-2141 [Electronic] England
• PMID: 36951278 (Publication Type: Observational Study, Multicenter Study, Journal Article)
• Copyright: © 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Chemical References

• Antineoplastic Agents
• venetoclax
• Bridged Bicyclo Compounds, Heterocyclic

Topics

• Humans
• Antineoplastic Agents (therapeutic use)
• Leukemia, Lymphocytic, Chronic, B-Cell (drug therapy, pathology)
• Retrospective Studies
• Tumor Lysis Syndrome (etiology, drug therapy)
• Bridged Bicyclo Compounds, Heterocyclic (adverse effects)